VETERINARY ONCOLOGY SERVICES, INC.
TAMPA, FLORIDA

Morphogenesis Inc. has developed, patented, and currently owns a comprehensive product portfolio of cellular and gene therapies that can detect, monitor and control cancer. Morphogenesis Inc.’s leadership in the companion animal cancer treatment market is being spearheaded by our wholly-owned subsidiary, Veterinary Oncology Services. While Morphogenesis and its breakthrough research and development work is privately funded, Morphogenesis has been the recipient of investments and grants from the Walt Disney Memorial Cancer Institute, the National Institutes of Health Small Business Innovation Research, Product Assistance for Cellular Therapies, and Qualifying Therapeutic Discovery Project. In 2009, Morphogenesis Inc. was a finalist in the World Technology Summit alongside Facebook, YouTube, Amazon, and The Honda Motor Company. Morphogenesis was recognized among those companies “doing the ‘work having the greatest likely long-term significance’ in their fields.” Morphogenesis is a clinical stage research and development biotech company with a wide range of enabling cell and gene therapy technologies and a comprehensive product portfolio addressing the detection, monitoring and control of cancer. Morphogenesis was founded on the principle of ‘biotechnology’ in its purest form, i.e. the use of biological processes, organisms and systems to manufacture products that solve complex problems and improve the quality of human life. We have focused on cell and gene therapies because these approaches lie at the heart of biological processes and their use capitalizes on the vast ability of biological systems to solve complex biological issues. Morphogenesis formed Veterinary Oncology Services, Inc. in order to make the personalized form of ImmuneFx available for companion animals. Customization of the ImmuneFx technology for each specific patient has been made possible by the careful honing of the process so that it is rapid, efficient and cost effective. Personalized ImmuneFx is an entirely new and effective weapon for veterinarians to use in their fight against cancer in companion animals. Our team could be described as passionate, dedicated, committed, motivated or driven, but we believe we are all of those things. As the business of science evolves, we know that maintaining status quo is not an option, and we are fully committed to leading the charge into the scientific unknowns for the betterment of people’s lives and will continue being pioneers leading the way. At Morphogenesis we believe that and we continuously seek to embrace these changes, adapt to them and influence them. That is who we are at Morphogenesis and THAT is what keeps us going… Pat is a co-founder of Morphogenesis, Inc. and has served the Company as Chief Executive Officer since 2003. Pat also served as Morphogenesis’ Chief Operating Officer from 1996 until 2003. Pat previously served as Division Director of Cancer Molecular Biology at the Walt Disney Memorial Cancer Institute, where she initiated and led the multifaceted molecular biology, gene targeting, gene therapy, gene delivery, and universal stem cell projects. Pat holds degrees from the University of Florida in Anthropology, Plant Pathology, Immunology and Medical Microbiology with specialties in Hematology and Oncology and has held faculty positions at several Florida State Universities. Scott came to Morphogenesis, Inc. in 2012 with over thirty years of experience in the broker-dealer and real estate industries. He has management experience in accounting, budgeting, financing, investments, and regulatory relations. Scott earned his BS from Northern Illinois University and his MBA from Tampa College. He has previously been the CFO for Westchase Holdings, InvestIN.com, and Investment Firm of Keogler, Morgan and Company. Angela joined the Morphogenesis team as an intern in 2012, worked her way into a Research Associate position and is currently the Laboratory Manager. Angela holds a Professional Science Masters in Biotechnology degree from the University of South Florida. She obtained her Bachelor’s degree in Science from Radford University in Radford, Virginia, and holds a minor in Business and Technical Writing. While attending Radford, she took the opportunity to volunteer over 500 hours on a genetics research project to gain experience in common molecular techniques. While earning her degrees, Angela obtained 10 years of experience in ISO certified manufacturing facilities. During this time, she gained experience in proper documentation, inventory tracking, team building, troubleshooting equipment and problem-solving. Angela’s manufacturing experience presented the opportunity to discern the most effective and efficient ways to complete many different types of tasks. Ashraf joined Morphogenesis, Inc., in 2013. He holds a Professional Science Master’s degree in Biotechnology with a Graduate Certificate in Bioinformatics from the University of South Florida in Tampa. Ashraf is a certified Medical Technologist (Clinical Laboratory Scientist) by the American Medical Technologists (AMT), the American Society for Clinical Pathology (ASCP) with a specialty in Hematology, and by the Florida Department of Health as a Medical Technologist in Hematology. He joins Morphogenesis with approximately 10 years of Clinical Laboratory, technical and management experience. He is also certified as a Clinical Laboratory Quality Manager by the University of British Columbia. His prior professional appointments include Product Management at Abbott Laboratories’ Diagnostics Division. Ashraf was named an ASCP 40 under 40 honoree in 2014, an international program that recognizes the future generation of laboratory leaders. Ashraf joined the Morphogenesis’ team in the capacity of Chief Clinical Officer as a liaison between Morphogenesis, Inc. and the Company’s clinical trial sites to ensure accurate policy and practice enforcement in addition to his role as Data Monitor. In 2018 Ashraf was appointed as the Company’s Director of Regulatory Affairs.